FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person— LEDERMAN SETH					2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 06/29/2022							X Officer (give title below) Other (specify below) Chief Executive Officer				
(Street)				4	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)				
CHATHAM, NJ 07928												_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City))	(State)	(Zip)			Table	e I - No	n-Derivat	ive Sec	curities	Acquir	red, Dispo	osed of, or I	Beneficially Ov	vned	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Execut any	Deemed 3. ceution Date, if Transact Code (Instr. 8) Code		8)		sposed of B For a and 5) B		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			7. Nature of Beneficial Ownership (Instr. 4)	Indirect		
Common Stock, \$0.001 par value		06/29/2022			P		20,000	` ′	¢.	24,235 (1)		I	By IRA Account			
Common par value	Stock, \$0.	.001									3,505 (1)		D			
Common Stock, \$0.001 par value		.001									1 (1)		I	By spouse		
Common Stock, \$0.001 par value		.001									1 (1)		I	By Leder Laboratories, Inc. (2)		
Common Stock, \$0.001 par value		.001									1 ⁽¹⁾		I	By Starling Pharmaceuticals, Inc. (2)		
Common par value	Stock, \$0.	.001									7 (1)			I	By Ledern Co., LLC	
Common Stock, \$0.001 par value		.001									2 (1)		I	By L&L Technologies, LLC (2)		
Common Stock, \$0.001 par value		.001									2 (1)			By Targent Pharmaceuticals, LLC (2)		
Reminder: 1	Report on a s	eparate li	ne for each class o		erivative Sec			Persons containe the form	who ed in t	his for lays a	rm are curren	not requ tly valid	OMB conf	ormation pond unless rol number.		74 (9-02)
	_			(e.,	g., puts, call	s, warr		ptions, cor	vertib	le secu	rities)					l
1. Title of Derivative Conversion Security or Exercise (Instr. 3) Price of Derivative Security Security 3. Transaction Date (Month/Day/Y		Execution Date, if Transa		Code	of De See Ac (A Dis of (In		and Expi	and Expiration Date (Month/Day/Year) Am Und Sec		Amor Unde Secur (Instr	ele and unt of crlying crities c. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershij (Instr. 4)	

	Code	V (A)	Exercisable	Expiration Date	Title	Amount or Number of Shares			
--	------	-------	-------------	--------------------	-------	----------------------------------------	--	--	--

Reporting Owners

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X		Chief Executive Officer				

Signatures

/s/ Seth Lederman	07/01/2022
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares reported reflect a 1-for-32 reverse stock split effective May 17, 2022.
- (2) Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.